Jane Street Group, LLC Mereo Biopharma Group PLC Transaction History

Jane Street Group, LLC

$445 Billion
Q3 2024

A detailed history of Jane Street Group, LLC transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Jane Street Group, LLC holds 214,635 shares of MREO stock, worth $755,515. This represents 0.0% of its overall portfolio holdings.

Number of Shares

214,635

Previous 84,593 153.73%

Holding current value

$755,515

Previous $304,000 190.13%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.45 - $4.87 $448,644 - $633,304	130,042 Added 153.73%	214,635 $882,000
Q2 2024 Aug 14, 2024	SELL	$2.58 - $4.25 $5,882 - $9,690	-2,280 Reduced 2.62%	84,593 $304,000
Q1 2024 May 15, 2024	BUY	$2.3 - $4.05 $199,807 - $351,835	86,873 New	86,873 $286,000
Q3 2023 Nov 14, 2023	SELL	$1.15 - $1.67 $1,680 - $2,439	-1,461 Reduced 7.79%	17,285 $22,000
Q2 2023 Aug 14, 2023	SELL	$0.79 - $1.43 $57,154 - $103,456	-72,347 Reduced 79.42%	18,746 $24,000
Q1 2023 May 15, 2023	SELL	$0.71 - $1.22 $72,326 - $124,280	-101,869 Reduced 52.79%	91,093 $64,000
Q4 2022 Feb 14, 2023	BUY	$0.5 - $1.01 $9,588 - $19,367	19,176 Added 11.03%	192,962 $144,000
Q3 2022 Nov 14, 2022	BUY	$0.82 - $1.73 $124,444 - $262,548	151,762 Added 689.08%	173,786 $150,000
Q2 2022 Aug 16, 2022	BUY	$0.33 - $1.69 $7,267 - $37,220	22,024 New	22,024 $25,000
Q2 2021 Aug 16, 2021	SELL	$2.94 - $4.08 $138,823 - $192,653	-47,219 Closed	0 $0
Q1 2021 May 18, 2021	BUY	$2.6 - $4.43 $62,870 - $107,121	24,181 Added 104.96%	47,219 $159,000
Q4 2020 Feb 17, 2021	BUY	$1.95 - $3.6 $44,924 - $82,936	23,038 New	23,038 $82,000

Others Institutions Holding MREO

# of Institutions

Shares Held

107M

Call Options Held

209K

Put Options Held

479K

View Full List

About Mereo Biopharma Group plc

Ticker MREO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,986,000
Market Cap $440M
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...

More about MREO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC Mereo Biopharma Group PLC Transaction History